When created in 2010, CELLforCURE was a coordinator of a French national consortium, C4C, supported by the French government. This project aimed at industrializing cell and gene therapies, in order to meet the French and European needs in this field, in compliance with the new European regulation on the Advanced Therapy Medicinal Products (ATMP).
The C4C consortium, gathering academic institutions and SMEs, made possible the establishment in France (Les Ulis) of the first ever technical and industrial facility dedicated to cell and gene therapies, this facility being operated by CELLforCURE.
The C4C consortium gathers, along with public and private players, seven hospitals including academic research centers, the whole consortium supporting five ATMPs to bring them to the market.
CELLforCURE is now an expert in the processing of a broad spectrum of cell types for autologous as well as allogeneic indications (e.g. MSC, HSC, lymphocytes and other immuno-competent cells and progenitors, myoblast progenitors, epithelial sheets, genetically modified cells including allogeneic CAR-T Cells..
A wide portfolio of projects
CELLforCURE currently conducts a wide range of projects, developing partnerships with hospitals, SMEs, top pharmaceutical companies, all projects addressing different medical needs.
CELLforCURE is also committed in strategic projects, on a long term basis, with specific partners, in a strict GMP and cGMP framework. An example of this is CELLforCURE’s bioproduction agreements with CELLECTIS, a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART).